Early Alzheimer's diagnostics: pTau217, RNA biomarkers, digital tools
Key Questions
What blood tests are FDA-cleared for early Alzheimer's detection?
FDA-cleared pTau217 blood tests represent a major advance in early diagnostics. The Abbott-ALZpath partnership is working to scale these tests on Alinity platforms for broader access.
How do RNA biomarkers from Mount Sinai aid Alzheimer's detection?
Mount Sinai researchers have identified blood RNA biomarkers in neuronal exosomes called SECmeres for early detection. This liquid biopsy approach offers a promising non-invasive option.
What digital tools can detect Alzheimer's changes earlier than traditional tests?
AI analysis of speech and handwriting, wearable sensors, and validated smartphone memory tests can identify decline months faster than clinical assessments. These tools complement emerging blood-based methods.
Rapidly evolving field with FDA-cleared blood tests (pTau217), emerging RNA-based liquid biopsy (Mount Sinai), AI speech/handwriting analysis, and wearable sensors. Abbott-ALZpath partnership aims to scale pTau217 testing on Alinity platforms. Mount Sinai identifies blood RNA biomarkers in neuronal exosomes (SECmeres) for early detection. New: genetic-sleep interaction study links AQP4 variants to Alzheimer's risk via glymphatic clearance, strengthening sleep as a modifiable factor. Down syndrome research highlights near-universal Alzheimer's pathology by age 40. Financial problems and sleep disturbances are validated early signs. FDA approval of pTau217 tests is a major step, but Medicare coverage gap and rural access remain critical bottlenecks. New: smartphone memory tests validated to detect decline months faster than traditional clinical tests.